12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
12 patients won't be enough to approve MPL for global use but it...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $86.77M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.8¢ | 19.5¢ | $67.86K | 346.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 360690 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 792103 | 8 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |